Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07141706 · ClinicalTrials.gov registry record · Phase 1
A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors
A Phase 1 study of Advanced/Metastatic Solid Tumors, sponsored by DualityBio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 233
- Enrollment target
- 5
- Study locations
NCT07141706: Recruiting Phase 1 study of Advanced/Metastatic Solid Tumors, sponsored by DualityBio.
NCT07141706 is a Phase 1 study of Advanced/Metastatic Solid Tumors that is actively recruiting participants, run by DualityBio. The registered enrollment target is 233 participants, below the 271-participant average among 4 other Advanced/Metastatic Solid Tumors trials with a reported enrollment target (14% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07141706, a Phase 1 study of Advanced/Metastatic Solid Tumors, is actively recruiting participants, sponsored by DualityBio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 233 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a multicenter, open-label, multiple-dose, FIH Phase 1a/1b study. Phase 1a adopts an accelerated titration design and a BOIN design to identify the MTD or MAD of DB-1317; Phase 1b includes up to 3 randomized dose expansion cohorts to further evaluate the safety, tolerability and preliminary efficacy of DB-1317 in selected solid tumors and to identify optimal RP2D.
Primary Outcome
Percentage of participants in Phase 1a with DLTs
Conditions Studied
Interventions
- DRUG DB-1317
Study Locations (5)
Texas
- USA02-0 - Houston
- USA03-0 - San Antonio
California
- USA04-0 - Los Angeles
Virginia
- USA01 - Fairfax
New South Wales
- AUS01-0 - Randwick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 233 participants |
| Start Date | 2025-09-23 |
| Est. Completion | 2028-06 |
| Phase | Phase 1 |
What NCT07141706 shows while recruiting
NCT07141706 is an interventional study that assigns participants to a tested intervention. The registered 233 participants enrollment target is mid-sized for trials with a published cap, below the 271-participant average among 4 other Advanced/Metastatic Solid Tumors trials with a reported enrollment target (14% lower).
The record links to 1 condition, with Advanced/Metastatic Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which DB-1317 is the first listed.
NCT07141706 lists 5 locations in 4 states (Texas, California, Virginia).
Frequently Asked Questions
What is clinical trial NCT07141706 about?
NCT07141706 is a clinical study titled "A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors". This is a multicenter, open-label, multiple-dose, FIH Phase 1a/1b study. Phase 1a adopts an accelerated titration design and a BOIN design to identify the MTD or MAD of DB-1317; Phase 1b includes up to 3 randomized dose expansion cohorts to further evaluate the safety, tolerability and preliminary e...
What is the current status of trial NCT07141706?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 233 participants. The study started on 2025-09-23. Estimated completion is 2028-06.
What conditions does trial NCT07141706 study?
This clinical trial studies the following conditions: Advanced/Metastatic Solid Tumors.
What interventions are being tested in trial NCT07141706?
The interventions under investigation include: DB-1317 (DRUG).
Who is sponsoring clinical trial NCT07141706?
This trial is sponsored by DualityBio, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07141706 being conducted?
This trial has 5 study locations across California, Texas, Virginia, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced/Metastatic Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06993844 · 233 participants · Phase 1
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- NCT04942717 · 234 participants · NA
Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
- NCT05208671 · 234 participants · NA
Nutrition to Optimize, Understand, and Restore Insulin Sensitivity in HIV for Oklahoma
- NCT05444465 · 234 participants · NA
Use of the REGENETEN™ Bioinductive Implant System in High Grade Partial-thickness Tears
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI